产品说明书
Tigecycline
 |
同义名 : | GAR-936;Glycylcycline;trade name: TYGACL.;TBG-MINO;WAY-GAR-936 |
| CAS号 : | 220620-09-7 | |
| 货号 : | A175151 | |
| 分子式 : | C29H39N5O8 | |
| 纯度 : | 98% | |
| 分子量 : | 585.649 | |
| MDL号 : | MFCD00935753 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 25 mg/mL(42.69 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 8 mg/mL(13.66 mM)，配合低频超声，并水浴加热至45℃助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Tigecycline is a broad-spectrum, first-in-class glycylcycline antibiotic currently used to treat complicated skin and intra-abdominal infections, as well as community-acquired pneumonia. Tigecycline also has in vitro and in vivo activity against acute myeloid leukemia (AML) due to its ability to inhibit mitochondrial translation. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL[3]. MIC50 and MIC90 are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii), respectively[4]. Tigecycline monotherapy was associated with a OR of 2.73 (95% CI 1.53-4.87) for mortality compared with tigecycline combination therapy (6 studies; 250 patients), without heterogeneity. The combined treatment with tigecycline may be considered the optimal option for severely ill patients with BSI(bloodstream infections) [5]. Tigecycline is a vital antibiotic treatment option for infections caused by multiresistant bacteria in the intensive care unit (ICU). No dose adjustment of tigecycline seems necessary in CRRT(continuous renal replacement therapy) [6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.71mL 0.34mL 0.17mL |
8.54mL 1.71mL 0.85mL |
17.08mL 3.42mL 1.71mL |
| 参考文献 |
|---|